Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 7/20 | 0.55 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.50 |
| ▸ | SELE | P16581 | 1/20 | 0.50 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426357 | 0.83 | ICAM1 (0.73) | HTTMAPK1SMN1; SMN2EGFRPDE5A | |
| SCHEMBL5438609 | 0.82 | ICAM1 (0.60) | HTTMAPK1SMN1; SMN2EGFRPDE5A | |
| SCHEMBL27697469 | 0.80 | NPC1 (0.49) | HTTSMN1; SMN2EGFRAURKARPS6KB1 | |
| SCHEMBL5423720 | 0.79 | NPC1 (0.55) | HTTMAPK1SMN1; SMN2AURKARPS6KB1 | |
| SCHEMBL5429306 | 0.76 | EGFR (0.53) | HTTMAPK1EGFRLMNAICAM1 | |
| SCHEMBL4868121 | 0.76 | MAPK1 (0.74) | HTTMAPK1SMN1; SMN2EGFRPDE5A | |
| SCHEMBL3345323 | 0.73 | TP53 (0.60) | HTTMAPK1SMN1; SMN2EGFRPDE5A | |
| SCHEMBL5435674 | 0.73 | ICAM1 (0.60) | HTTMAPK1SMN1; SMN2LMNATP53 | |
| SCHEMBL21541991 | 0.72 | APP (0.62) | HTTMAPK1SMN1; SMN2EGFRMEN1 | |
| SCHEMBL6833333 | 0.71 | EGFR (1.00) | HTTMAPK1SMN1; SMN2EGFRPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| CN-101061122-A | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| EP-1799687-A1 | NOVEL THIENO-PYRIDINE AND THIENO-PYRIMIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006030031-A1 | NOVEL THIENO-PYRIDINE AND THIENO-PYRIMIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275984-A1 | Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors | GRM2, GRIA2, GRM1 | HTT 2147/4885MAPK1 1760/4885SMN1; SMN2 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.